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Background: Although combination therapy with bronchodilators is recommended for chronic 
obstructive pulmonary disease (COPD), there is insufﬁ  cient evidence for the efﬁ  cacy of some 
combinations of long-acting bronchodilators.
Objective: We investigated the effects of a combination therapy with tiotropium and theophyl-
line in COPD patients.
Methods: In a 12-week, open-labeled, parallel-group randomized study, pulmonary functions 
and dyspnea scores were compared between the combination and theophylline alone therapy at 
baseline, and 4 and 8 weeks after randomization in COPD.
Results: Sixty-one COPD patients completed the trial (31 combination therapy, 30 theophylline 
alone; mean age 70 years; 58 males; mean dyspnea score 2.0 and forced expiratory volume in 
one second (FEV1) 1.5 L [62.5% predicted]). FEV1 in the combination group, but not in the 
theophylline alone, was signiﬁ  cantly increased at 4 (1.56 ± 0.13 L, p  0.001) and 8 weeks 
(1.60 ± 0.13 L, p  0.001) from the baseline (1.40 ± 0.12 L). In the combination group, but not 
the theophylline alone group, the dyspnea score was signiﬁ  cantly improved after 4 (p  0.01) 
and 8 weeks (p < 0.05) compared with baseline. In 17 patients who did not receive theophyl-
line at screening, treatment with 4 or 8 weeks of theophylline alone did not improve dyspnea 
score or FEV1.
Conclusion: Addition of tiotropium therapy to theophylline treatment can improve dyspnea 
and pulmonary function in COPD. Although this study did not assess whether there was any 
beneﬁ  t of adding theophylline to patients treated with tiotropium, tiotropium can be a useful 
addition in COPD already treated with theophylline.
Keywords: chronic obstructive pulmonary disease, long acting anticholinergics agent, tiotro-
pium, slow release theophylline, combination therapy
Introduction
Chronic obstructive pulmonary disease (COPD) is characterized by progressive air-
way obstruction, chronic respiratory symptoms, and impaired health status, and it is a 
leading cause of morbidity and morality worldwide (Gold 2006). COPD is treatable, 
and pharmacological treatment is effective in controlling symptoms and health status. 
In particular, the use of bronchodilators plays a central role in the pharmacological 
treatment of symptomatic COPD patients. Bronchodilators improve airway obstruc-
tion, symptom control, health status, and health-related quality of life (QOL), and they 
reduce the frequency of exacerbations (Donohue 2005; Gold 2006).
Tiotropium bromide is a long-acting anticholinergic that provides sustained bron-
chodilation through prolonged M3 muscarinic receptor blockade (Disse et al 1999). 
Previous studies have shown that inhaled tiotropium improves pulmonary function, 
dyspnea, and QOL in COPD to a signiﬁ  cantly greater extent than placebo or the 
short-acting anticholinergic ipratropium (Casaburi et al 2002; Vincken et al 2002). 
Tiotropium also reduces COPD exacerbations and may reduce related utilization of International Journal of COPD 2008:3(1) 138
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health-care facilities in patients with moderate to severe 
COPD (Niewoehner et al 2005; Dusser et al 2006). Fur-
thermore, one recent study based on a retrospective 1-year 
analysis has raised the possibility that tiotropium is associated 
with a reduced rate of loss of forced expiratory volume in 
1 second (FEV1) (Anzueto et al 2005).
Oral slow-released theophylline is used widely as a 
bronchodilator worldwide (Turner-Warwick 1957; Jackson 
et al 1964; Mitenko and Ogilvie 1973). Previous studies have 
reported that long-term theophylline use for COPD results 
in improvement of pulmonary functions, including vital 
capacity (VC), FEV1, minute ventilation, and gas exchange 
(Murciano et al 1989). Theophylline also has a beneﬁ  cial 
effect on exercise endurance in COPD (Guyatt et al 1987). 
Recent studies have shown that theophylline reduces the 
numbers of neutrophils and concentrations of interleukin-8 in 
the airways of COPD patients (Culpitt et al 2002). Low-dose 
theophylline can also prevent oxidative stress, and it restores 
corticosteroid responsiveness (Ito et al 2002). These results 
suggest that theophylline has anti-inﬂ  ammatory effects in 
COPD, as it does in asthma (Sullivan et al 1994).
The GOLD (Global Initiative for Chronic Obstructive 
Lung Disease) guidelines recommend combination therapy 
with different potential bronchodilators for the pharmaco-
logical treatment of COPD (Gold 2006). Theophylline has 
an additional effect in the clinical improvement of COPD 
when it is used in combination with a long-acting β2-agonist 
(LABA) (Zuwallack et al 2001). However, few investiga-
tions have reported the efﬁ  cacy of combination therapy with 
inhalation of the long-acting anticholinergic tiotropium and 
oral administration of slow-release theophylline in COPD 
patients. In Japan, theophylline is prescribed for most COPD 
patients (Ichinose et al 2006). Our purpose was to investigate 
the efﬁ  cacy and safety of add-on treatment with tiotropium 
in COPD patients treated with theophylline.
Material and methods
The study was performed at Kurume University Hospital and 
at each medical institute of the Kurume COPD Study Group. 
The protocol was designed in accordance with good clinical 
practice and the latest revisions to the Declaration of Helsinki, 
and was approved by the institutional ethics committees of 
Kurume University and each medical institute.
Subjects
COPD patients 40 years old and with a cigarette smok-
ing history of 10 pack-years and respiratory symptoms 
related to COPD were enrolled in the study. All patients 
were diagnosed on the basis of clinical history, physical 
examination, chest X-ray, chest computed tomography, and 
pulmonary function tests, in accordance with the clinical 
criteria for the diagnosis and severity of COPD by the GOLD 
guidelines (Gold 2006). Patients with a history of asthma, 
atopy, absolute peripheral eosinophil count 600 mm3, 
and/or reversibility of FEV1 by 200 mL and 12% after 
inhalation of 200 µg salbutamol were carefully excluded. 
Patients who had a history of renal failure, moderate to 
severe prostatic hypertrophy or bladder-neck obstruction, 
narrow-angle glaucoma, heart failure, arrhythmia, bron-
chiectasis, pneumoconiosis, old mycobacterial infections, 
interstitial pneumonia, mental disorders, lung surgery, or 
any malignancies were also excluded. Five patients (16.6%) 
in the theophylline alone group and two patients (6.5%) in 
the combination group were being treated with inhaled cor-
ticosteroids at the screening visit. There was no signiﬁ  cant 
difference of number between the two groups (p = 0.2554). 
Written informed consent was obtained from all patients.
Study design
The study was performed over a 12-week period. We used an 
open-labeled, parallel-group, randomized design to compare 
the efﬁ  cacy and safety of the addition of 18 µg inhaled tiotro-
pium once daily to theophylline in stable COPD patients. The 
primary end-point for this study was the change in FEV1 from 
baseline to the end of 8 weeks after treatment, and the sec-
ondary end-points were the British MRC (Medical Research 
Council) dyspnea scale and forced vital capacity (FVC).
At the first visit, each patient underwent recording 
of medical, occupational, and smoking history; physical 
examination; chest radiography, including high-resolution 
computed tomography; electrocardiogram; blood test-
ing; and spirometry as screening tests to ensure that they 
met the inclusion criteria. The spirometry was performed 
before and after inhalation of a bronchodilator at the ﬁ  rst 
visit. Dyspnea was scored using the British MRC dyspnea 
scale (Moor-Jankowski 1976). Patients who met all the 
criteria were enrolled and given 200 mg theophylline twice 
daily for 4 weeks (a run-in period). The patients had been 
receiving different doses of theophylline, or none, before 
the run-in period. In those patients who had been receiv-
ing higher doses, the dose was reduced to 200 mg twice 
daily, as reported in previous studies, to prevent high serum 
concentrations (Kelly 1987; Barnes 1997). None of the 
patients was treated with anti-histamines, anti-leukotrienes, 
cromolyn, β-blockers, ACE inhibitors, oral prednisolone, 
and/or LABAs during the study. Some of the patients had International Journal of COPD 2008:3(1) 139
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discontinued these medications at least 4 weeks before 
enrollment. Patients were excluded if they had experienced 
an exacerbation within 4 weeks before enrollment. The use 
of a short-acting β2-agonist or short-acting anticholinergic 
on demand was permitted.
Following a 4-week run-in period (the end of which was 
deﬁ  ned as the baseline), patients were randomized to two 
groups. In one group, 18 µg of tiotropium was added on 
once daily from 6:00 to 8:00 am (combination group), and 
the other continued with the theophylline alone (theophylline 
alone group) for 8 weeks (the end of the treatment period). 
Patients who developed emesis or anorexia associated with 
the theophylline were withdrawn from the study. Smoking 
status and participation in rehabilitation programs were not 
altered during the trial.
Physical examinations, spirometry, and blood testing, 
including the monitoring of plasma concentrations of the-
ophylline and MRC scoring, were performed at screening and 
baseline, and after 4 and 8 weeks of treatment. Spirometry was 
performed at least three times between 11:00 am and noon, 
and the best dataset was accepted. On the basis of the results 
of a previous study, these values were regarded as the near-
peak changes after tiotropium inhalation (Disse et al 1999). 
Adverse events were evaluated during the study (Figure 1).
Data on exacerbations of COPD were also collected 
throughout the trial. Information on exacerbation was 
obtained by direct questioning of each patient. Exacerbation 
was deﬁ  ned in accordance with the description by Rodrignez-
Roisin (2000).
Statistical analysis
The number of subjects completing the study to the stage of 
primary end-point (FEV1) testing was 61, the experiment had 
90% validity at the 5% signiﬁ  cance level in detecting dif-
ferences between treatments, as reported in previous studies 
(Hirata et al 2003; Ichinose et al 2003).
Demographic data and MRC score were expressed as 
mean ± SD. Comparisons in the demographic characteris-
tics of patients with COPD between the combination and 
theophylline alone groups were analyzed by Fisher’s exact 
test. All data on spirometry and the time course of percent-
age change in pulmonary function since the screening visit 
were expressed as means ± SEM. Mean percentage changes 
between baseline (end of the run-in period) and after 4 and 
8 weeks of treatment (treatment period) in each group were 
calculated and then compared. The unpaired t-test was used 
for comparison between the two groups. Two-way ANOVA 
was used for comparison of the time course data of each 
Figure 1 Study design.
Notes: †British Medical Research Council score. Combination therapy: theophylline with tiotropium.
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group at the baseline and after 4 and 8 weeks of treatment. 
MRC scoring of the time course data of each group was 
performed by non-parametric two-way ANOVA corrected 
by post-testing. The relationship between the changes in 
each spirometric parameter and MRC score was tested by 
Spearman’s non-parametric correlation test. Data on the 
plasma concentration of theophylline were expressed as 
means ± SD and compared between the two groups by an 
unpaired t-test. Differences were considered statistically 
signiﬁ  cant when the p value was less than 0.05.
Results
Patients
Demographic characteristics at the baseline are shown in 
Table 1. There was no signiﬁ  cance difference in demographic 
characteristics between the two groups at the end of the 
run-in period. Seventy-seven COPD patients were matched 
to the entry criteria and enrolled in the study; they received 
theophylline (200 mg twice daily) for 4-weeks as a run-in 
period. During the run-in period, 13 patients were withdrawn 
from the study: 7 patients had adverse events associated 
with the theophylline (anorexia, 4; emesis, 1; ischuria, 1; 
and stomatitis, 1); 4 patients refused for personal reasons 
to continue; 1 patient had accompanying asthma, and one 
had an exacerbation of COPD. During the 8-week treatment 
period, two and one patient dropped out from the combina-
tion and theophylline alone groups, respectively. Finally, 
data on 61 COPD patients (31 combination; 30 theophylline 
alone) were used in the analysis (Figure 2). No subject in 
either group experienced disease exacerbation from baseline 
to 8 weeks.
Pulmonary function tests
The FVC and FEV1values in the combination therapy 
group were signiﬁ  cantly increased 4 and 8 weeks after the 
addition of tiotropium, when compared with the baseline 
(Figure 3a, b). The increase in FEV1 from the baseline was 
0.17 ± 0.03 L at 4 weeks and 0.21 ± 0.03 L at 8 weeks. 
In contrast, these effects were not observed in the the-
ophylline-alone group. The percentage changes in FVC 
and FEV1 from the baseline were signiﬁ  cantly increased 
at 4 and at 8 weeks in the combination therapy group, 
but not in the theophylline-alone group (Figure 3c, d). In 
addition, the percentage change in FEV1 in the combina-
tion therapy group was signiﬁ  cantly greater than that in 
the theophylline-alone group.
Figure 4 shows the results from 42 subjects from both 
groups who did not receive theophylline at screening (25 
combination; 17 theophylline-alone). Theophylline-alone 
group did not cause a signiﬁ  cant improvement in pulmonary 
function and symptoms over the 12 weeks (4-week run-in 
plus 8-week therapeutic period). However, in the combi-
nation therapy group, FVC and FEV1 were signiﬁ  cantly 
increased after the addition of tiotropium.
Table 1 Characteristics of patients with COPD at baseline
  Theophylline-alone group  Combination group  p value
 (n  = 30)   (n = 31) 
Age, yr ± SD  71.8 ± 8.1  68.4 ± 9.1  NS
Sex, Female/Male  2/28  1/30  NS
Smoking history, Pack-yr ± SD  66.7 ± 57.2  57.5 ± 31.5  NS
  Current smoker, % patients  13 (44.3)  14 (45.2)  NS
Body mass index, kg/m2 21.8  ± 3.6  22.6 ± 3.0  NS
Severity of disease, n (%)     
  Mild (stage I)  8 (26.7)  4 (12.9)  NS
  Moderate (stage II)  12 (40.0)  13 (41.9)  NS
  Severe (stage III)  10 (33.3)  14 (45.2)  NS
MRC dyspnoea score, mean ± SD  2.0 ± 1.1  2.0 ± 1.1  NS
FVC (L), mean ± SD  2.8 ± 0.9  3.0 ± 0.8  NS
FEV1/FVC (%), mean ± SD  49.8 ± 12.4  47.1 ± 12.6  NS
Pre-medications, n (%)     
  Theophylline  11 (36.7)  6 (19.4)  NS
 Long-acting  β2-agonist  4 (13.3)  1 (3.2)  NS
 Short-acting  β2-agonist  7 (23.3)  2 (6.5)  NS
  Short-acting anticholinergic drug  2 (6.7)  2 (6.5)  NS
  Inhaled corticosteroid  5 (16.7)  2 (6.5)  NS
Abbreviations: FEV1, forced expiratory volume in one second; FVC, forced vital capacity; NS, not signiﬁ  cant; SD, standard deviation.International Journal of COPD 2008:3(1) 141
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Figure 2 Trial proﬁ  le.
Figure 3 Changes in FVC and FEV1 in the theophylline alone (white squares) and the combination therapy group (black squares). In a and b, absolute values of FVC and 
FEV1 are shown. In c and d, percentage changes in FVC and FEV1 from the baseline are shown.
Notes: *p  0.05, **p  0.01, ***p  0.001 compared with baseline values. †p < 0.05 between two groups.
Abbreviations: FVC, forced vital capacity; FEV1, forced expiratory volume in one second.
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After 8 weeks of treatment, VC, inspiratory capacity (IC), 
peak expiratory ﬂ  ow rate (PEFR), V ·
50, and V ·
25 were signiﬁ  -
cantly higher than the baseline values in the combination 
group. These effects were not observed in the theophylline-
alone group (Figure 5).
MRC score
MRC score was analyzed in 59 of 61 patients (two patients 
withdrew from the study at the stage of MRC scoring). MRC 
scores in the theophylline-alone group (n = 29) at screening, 
baseline, and 4 and 8 weeks after treatment were 2.00 ± 1.10, 
1.75 ± 1.14, 2.04 ± 0.94, and 2.04 ± 1.21, respectively. The 
respective MRC scores in the combination group (n = 30) 
were 2.03 ± 1.10, 2.03 ± 1.19, 1.57 ± 1.14, and 1.57 ± 1.14. 
When compared with the baseline values, the mean MRC 
score in the combination group was signiﬁ  cantly decreased 
by 0.46 (p  0.01) and 0.46 (p  0.05) at 4 and 8 weeks 
after treatment, respectively. The improvement was small 
but clinically meaningful, because the changes in MRC 
score were greater than those in a previous study (Akamatsu 
et al 2007). In contrast, there was no signiﬁ  cant change in 
the theophylline-alone group when compared with baseline. 
There was no signiﬁ  cant difference in MRC score between 
the two groups at each time point (Figure 6a).
Next, we performed a sub-analysis of 42 of these 59 
patients who were not receiving theophylline at screening to 
determine the therapeutic effects of theophylline itself. MRC 
scores at screening, baseline, and 4 and 8 weeks after treat-
ment in the theophylline-alone group (n = 17) were 1.85 ± 
1.14, 1.74 ± 1.15, 1.95 ± 1.03, and 1.88 ± 1.32, respectively. 
The respective MRC scores in the combination group (n = 25) 
were 2.08 ± 1.15, 2.12 ± 1.24, 1.60 ± 1.15, and 1.58 ± 1.21. 
When compared with the baseline values, the mean MRC 
score in the combination group was signiﬁ  cantly decreased 
Figure 4 Changes in FVC and FEV1 in the theophylline-alone (white squares, n = 17) and the combination therapy group (black squares, n = 25), in patients who did not 
receive regular treatment with theophylline at the time of screening. In a and b, absolute values of FVC and FEV1 are shown. In c and d, percentage changes in FVC and FEV1 
from the baseline are shown.
Notes: *p  0.05, **p  0.01, ***p  0.001 compared with the baseline values. †p  0.05 between two groups.
Abbreviations: FVC, forced vital capacity; FEV1, forced expiratory volume in one second.
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by 0.52 (p  0.01) and 0.54 (p  0.05) at 4 and 8 weeks, 
respectively, after treatment (Figure 6b).
Physical examination
No signiﬁ  cant difference was observed between the two 
groups in terms of respiratory rates, blood pressure, heart 
rates, body temperature, and oxygen saturation of arterial 
blood by pulse oximeter at the screening visit, at the baseline, 
and after 4 and 8 weeks of treatment with tiotropium (data 
not shown).
Serum theophylline concentrations at the baseline and 
after 4 and 8 weeks of treatment were 8.6 ± 5.0, 8.9 ± 5.5, 
and 8.5 ± 4.7 µg/mL in the theophylline-alone group, and 
9.5 ± 5.7, 9.4 ± 3.6, and 9.1 ± 4.9 µg/mL in the combina-
tion therapy group, respectively. There were no signiﬁ  cant 
differences between the two groups at any time. Serum the-
ophylline levels greater than 20 µg/mL were not observed 
in any patient.
Adverse events
During the run-in period, 7 patients dropped out because of 
theophylline-related adverse events, as described above. We 
observed 9 adverse events during the treatment period. Two 
and 7 adverse events were observed in the theophylline-alone 
group and the combination therapy group, respectively. In the 
theophylline-alone group, these events were anorexia (n = 1) 
and hematuria (n = 1). In the combination therapy group, they 
were dry mouth (n = 2), pharyngolaryngeal paresthesia (n = 3), 
fatigue (n = 1), and bitter taste (n = 1). One of the patients with 
emesis dropped out of the theophylline-alone group, and one 
with dry mouth and one with pharyngolaryngeal paresthesia 
dropped out of the combination therapy group.
Discussion
To our knowledge, this is the ﬁ  rst study to show the efﬁ  cacy 
and safety of tiotropium add-on therapy in COPD patients 
treated with theophylline. We demonstrated that add-on 
therapy with tiotropium signiﬁ  cantly improved the MRC 
dyspnea score and pulmonary function in COPD patients 
already being treated with theophylline. According to the 
GOLD guidelines, combination therapy with different kinds 
of bronchodilators is recommended for COPD patients, 
because it can improve efﬁ  cacy without increasing the risk 
of side effects, as compared with increasing the dose of 
monotherapy (Gold 2006).
Previous studies have reported that treatment with 
relatively low dose of theophylline has anti-inﬂ  ammatory 
effects in COPD patients (Culpitt et al 2002; Kobayashi 
et al 2004; Hirano et al 2006). These patients were treated 
with theophylline at 400 mg/day, and/or plasma levels 
Figure 5 Changes in VC, IC, PEFR, V ·
50 and V ·
25 at 8 weeks. Changes in VC, IC, PEFR, V ·
50, and V ·
25 at 8 weeks were analyzed in theophylline-alone (white bars, n = 26) and combi-
nation therapy (solid bars, n = 30) groups.
Notes: *p  0.05 compared with screening values. †p  0.05 between two groups.
Abbreviations: IC, inspiratory capacity; PEFR, peak expiratory ﬂ  ow rate;   VC, vital capacity.
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of theophylline were approximately 5 to 10 mg/L. These 
concentrations of theophylline had anti-inflammatory 
effects. However, these studies did not determine whether 
theophylline had clinical beneﬁ  ts on pulmonary function or 
physical condition in COPD patients. The Japanese Respira-
tory Society’s guidelines for the diagnosis and treatment of 
COPD suggested that low dose of theophylline may be effec-
tive for COPD patients, as high doses of theophylline have 
toxic effects (Guidelines for the Diagnosis and Treatment 
of COPD 2006). On the basis of these studies, we treated 
COPD patients with 400 mg theophylline (200 mg twice 
daily). Plasma levels of theophylline were approximately 
8 to 10 mg/L in these patients, and theophylline alone did 
not improve pulmonary function (FEV1) or MRC scores in 
30 COPD patients analyzed. Moreover, in 17 patients who 
were not receiving theophylline at screening, treatment with 
theophylline alone did not improve MRC score or FEV1. The 
possibility remains that this concentration of theophylline 
in the plasma may not exert sufﬁ  cient bronchodilatation 
(Mitenko and Ogilvie 1973). Here we evaluated whether the 
combination of theophylline and tiotropium could improve 
FEV1 and MRC scores in COPD patients, and we compared 
our results with those of previous studies in Japan (Hirata 
et al 2003; Ichinose et al 2003).
A study that compared the effects of the short-acting 
anticholinergic ipratropium and theophylline reported that 
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Figure 6 British Medical Research Council (MRC) scores 4 and 8 weeks after the addition of tiotropium. (a) MRC scores 4 and 8 weeks after the addition of tiotropium were 
analyzed in theophylline-alone (white bars, n = 29) and combination therapy (solid bars, n = 30) groups. (b) MRC scores 4 and 8 weeks after the addition of tiotropium were 
analyzed in 42 patients who were not receiving theophylline at the time of screening: theophylline-alone (white bars, n = 17) and combination therapy (solid bars, n = 25).
Notes: *p  0.05, p  0.01 compared with baseline values.
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improvement of pulmonary function and exercise endurance 
was signiﬁ  cantly greater in the combination therapy group 
than in each monotherapy group (Tsukino et al 1998). In 
addition, a combination of the short-acting anti-cholinergic 
oxitropium and theophylline improved QOL to a signiﬁ  cantly 
greater extent than did each monotherapy (Bellia et al 2002). 
Furthermore, combination treatment with a short-acting 
β2-agonist, a short-acting anticholinergic agent, and oral 
theophylline led to signiﬁ  cantly greater improvement in 
FEV1 compared with the results of monotherapy, without 
any severe adverse effects (Karpel et al 1994).
Long-acting bronchodilators have recently become stan-
dard medicines in the pharmacological treatment of COPD 
(Gold 2006). Therefore, the establishment of combination 
therapy for COPD with long-acting bronchodilators is an 
expected trend. Combination of the LABA salmeterol with 
theophylline leads to signiﬁ  cantly better pulmonary func-
tions, greater improvement in symptoms, improved reduction 
in the use of short-acting β2-agonists, and decrease in exac-
erbation frequency compared with the use of theophylline 
alone (Zuwallack et al 2001). In both stable COPD patients 
and those with exacerbations, combination therapy with the 
inhaled LABA formoterol and the inhaled long-acting anti-
cholinergic tiotropium improves pulmonary function indi-
cators such as FEV1, IC, and FVC to a signiﬁ  cantly greater 
extent than is seen with each agent alone (Di Marco et al 
2006; Van Noord et al 2006). A previous study also showed 
additional clinical improvement when COPD patients were 
treated with theophylline added to salmeterol (Zuwallack 
et al 2001). However, evidence of the effects of combina-
tion therapy with long-acting bronchodilators, especially 
anticholinergics and theophylline, is still scant.
One recent study reported the effect of combination 
therapy with tiotropium and theophylline (Cazzola and 
Gabriella Matera 2007). They investigated the additive effect 
of theophylline in patients with stable COPD who were 
receiving both tiotropium and formoterol. Although their 
ﬁ  ndings question the importance of adding theophylline in 
stable COPD patients already being treated with two long-
acting bronchodilators, they also indicate that some patients 
may beneﬁ  t from theophylline because of symptomatic 
improvement. We chose to investigate the effects of add-
ing tiotropium in patients already treated with theophylline 
because theophylline is widely used for COPD treatment, 
both in Japan and worldwide (Ichinose et al 2006).
Dyspnea upon exercise is one of the most important 
symptoms in patients with COPD. We used the MRC dys-
pnea score to assess symptoms: the MRC questionnaire can 
easily classify symptom severity. We demonstrated that 
the mean MRC dyspnea score in patients with combination 
therapy improved signiﬁ  cantly after both 4 and 8 weeks of 
tiotropium add-on therapy.
The beneﬁ  cial effect of combination therapy might be 
attributable to the different mechanisms of bronchodilation 
(Thirstrup 2000). Theophylline had been reported to have 
extrapulmonary effects, such as increased diaphragmatic 
contractility and reversed diaphragm fatigue, although the 
validity of these effects remains controversial (Aubier et al 
1981). There is also increasing evidence that low-dose the-
ophylline has anti-inﬂ  ammatory effects in asthma and COPD 
(Culpitt et al 2002; Cosio et al 2004; Barnes et al 2005).
The effects of treatment with tiotropium alone on pul-
monary function, when compared with placebo, include 
improvements in peak expiratory flow volume, FEV1, 
FVC, VC, and IC (Casaburi et al 2002; Vincken et al 2002; 
Brusasco et al 2003; Celli et al 2003; O’Donnell et al 2004; 
Van Noord et al 2006). Our ﬁ  ndings conﬁ  rmed these previ-
ous observations. In the study of Japanese COPD patients, 
the increase in peak FEV1 with tiotropium alone was 
0.20 ± 0.02 L after 6 months of treatment (Hirata et al 2003; 
Ichinose et al 2003). In our patients, addition of tiotropium 
to theophylline increased the mean FEV1 by 0.17 ± 0.03 L 
and 0.21 ± 0.03 L after 4 and 8 weeks, respectively. These 
increases in FEV1 were similar to those in other investiga-
tions (Hirata et al 2003; Ichinose et al 2003). Our present 
study did not include a group of patients treated with tio-
tropium alone, so we were unable to assess whether there 
was any beneﬁ  t of adding theophylline to patients treated 
with tiotropium. The above-mentioned recent study in 
which the add-on effect of theophylline was investigated in 
patients already being treated with tiotropium and formoterol 
reported a limited effect of theophylline add-on (Cazzola and 
Gabriella Matera 2007). Evaluation of all of these results 
together indicates that tiotropium is a useful addition in 
COPD patients already treated with theophylline.
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